Learn How Resilience's Idea To Clinic Can Accelerate Your Manufacturing Timeline To The FIH Clinical Study

Despite significant progress, translating novel drug discoveries into clinical trials remains a complex endeavor. This presentation explores how Resilience utilizes cutting-edge technologies to expedite this process, facilitating a smoother path from drug conception to first-in-human studies.

Our focus centers on three key advancements:

• Accelerated Regulatory Filing: We leverage a highly parallelized workflow, incorporating stable CHO cell lines and Leap-In Transposase technology, to significantly reduce the time frame between gene identification and regulatory filing for first-in-human trials.
• Efficient Candidate Selection: Bottlenecks associated with therapeutic screening and optimization are addressed using our cell-free protein synthesis platform. This enables rapid selection, generation, and parallel testing of thousands of unique drug candidates.
• Optimized Developability and Manufacturability: By employing iterative cycles that combine machine learning-based design, cell-free protein synthesis, and advanced molecular characterization techniques, we optimize therapeutic candidates for superior manufacturability and developability, thereby mitigating CMC (Chemistry, Manufacturing, and Controls) risks.

Through these advancements, Resilience empowers clients to navigate the often labyrinthine drug development and manufacturing journey, accelerating their path from initial concept to clinical trials.

This presentation was originally delivered at BPI on September 18, 2023.